Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENvue Medical, Inc.NAOV · Entity 8385 | Director | December 30, 2024 | January 03, 2025 |
| NeuBase Therapeutics, Inc.OHRP · Entity 109568 | Director | May 12, 2017 | October 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENvue Medical, Inc.
Report date December 30, 2024 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2034-12-30 | Direct | 20,000 |
Reported balance
After 2024-12-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-30 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the options vested on the date of grant in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2024 Long-Term Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options vested on the date of grant in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2024 Long-Term Incentive Plan.
NeuBase Therapeutics, Inc.
Report date May 12, 2017 · Filed October 18, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2022-05-11 | Direct | 500,000 |
Reported balance
After 2017-05-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-05-12 · Grant · Acquired 500,000 · Balance 500,000 F1: Reflects a reduction of options to purchase 250,000 shares of common stock subject to the stock option, the excess portion of shares of common stock subject to the stock options granted to the reporting person on May 12, 2017, in connection with the reporting person's appointment to the board of directors of the Issuer, which excess portion has been determined to have been in excess of annual plan limits set forth in the Issuer's 2016 Consolidated Stock Incentive Plan, and thus rescinded and canceled. F2: 250,000 shares of common stock subject to the stock option became exercisable immediately, and 125,000 shares of common stock subject to the stock option will become exercisable on each of May 12, 2018 and May 12, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a reduction of options to purchase 250,000 shares of common stock subject to the stock option, the excess portion of shares of common stock subject to the stock options granted to the reporting person on May 12, 2017, in connection with the reporting person's appointment to the board of directors of the Issuer, which excess portion has been determined to have been in excess of annual plan limits set forth in the Issuer's 2016 Consolidated Stock Incentive Plan, and thus rescinded and canceled.
F2: 250,000 shares of common stock subject to the stock option became exercisable immediately, and 125,000 shares of common stock subject to the stock option will become exercisable on each of May 12, 2018 and May 12, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Globis Acquisition Corp.
Report date June 09, 2022 · Filed June 14, 2022
Section 16 reporting ended · disclosed 2022-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-06-09 transaction · row 1
1 source rowRow 1 · 2022-06-09 · Other · Disposed 15,000 · Balance 0 F1: On June 9, 2022, the issuer consummated its initial business combination (the "Business Combination") with Forafric Global PLC. ("New Forafric"), a Gibraltar public company limited by shares. As described in Globis Acquisition Corp.'s Current Report on Form 8-K (File No. 333-262126) filed on June 9, 2022 (the "Form 8-K"), in connection with the closing of the Business Combination, each share of Common Stock was exchanged for one ordinary share, nominal value $0.001 per share, of New Forafric (each, an "Ordinary Share"). |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2025-12-10 | Direct | 0 |
Reported balance
After 2022-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-09 · Other · Disposed 20,000 · Balance 0 F3: As described in the Form 8-K, in connection with the closing of the Business Combination, the private placement warrants were exchanged for warrants to acquire Ordinary Shares at an exercise price of $11.50 per share. F2: The warrants became exercisable upon the completion of the Business Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 9, 2022, the issuer consummated its initial business combination (the "Business Combination") with Forafric Global PLC. ("New Forafric"), a Gibraltar public company limited by shares. As described in Globis Acquisition Corp.'s Current Report on Form 8-K (File No. 333-262126) filed on June 9, 2022 (the "Form 8-K"), in connection with the closing of the Business Combination, each share of Common Stock was exchanged for one ordinary share, nominal value $0.001 per share, of New Forafric (each, an "Ordinary Share").
F2: The warrants became exercisable upon the completion of the Business Combination.
F3: As described in the Form 8-K, in connection with the closing of the Business Combination, the private placement warrants were exchanged for warrants to acquire Ordinary Shares at an exercise price of $11.50 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2024 Filed Jan 3, 2025 02:21 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-25-000136 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-12-30 F1 · derivative.exercise_date: 100% of the options vested on the date of grant in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2024 Long-Term Incentive Plan. Read SEC document |
| January 23, 2024 Filed Feb 24, 2024 00:18 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 16,666 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001493152-24-007743 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2024-01-23 F1 · derivative.exercise_date: 100% of the option vested on January 23, 2024, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| November 29, 2023 Filed Dec 5, 2023 01:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,875 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001493152-23-043635 · ownership.xml · derivative · entry 5 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,875 shares Expires 2032-09-13 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. F4 · derivative.exercise_date: 25% of the option vested on September 13, 2022 (the "2022 Date of Grant"), with an additional 25% to vest on the three-month anniversary of the 2022 Date of Grant, a further 25% to vest on the six-month anniversary of the 2022 Date of Grant, and the final 25% to vest on the nine-month anniversary of the 2022 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| November 29, 2023 Filed Dec 5, 2023 01:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,875 | $0.00 Strike: $20.20 | $0.00 |
DisclosureSEC source: 0001493152-23-043635 · ownership.xml · derivative · entry 4 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,875 shares Expires 2031-12-29 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. F3 · derivative.exercise_date: 25% of the option vested on December 29, 2021 (the " 2021 Date of Grant"), with an additional 25% vested on the three-month anniversary of the 2021 Date of Grant, a further 25% vested on the six-month anniversary of the 2021 Date of Grant, and the final 25% vested on the nine-month anniversary of the 2021 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| November 29, 2023 Filed Dec 5, 2023 01:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 4,250 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001493152-23-043635 · ownership.xml · derivative · entry 3 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,250 shares Expires 2030-12-22 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. F2 · derivative.exercise_date: 20% of the option vested on December 22, 2020 (the "2020 Date of Grant"), with an additional 20% vested on the three month anniversary of the 2020 Date of Grant, a further 20% vested on the six month anniversary of the 2020 Date of Grant, a further 20% vested on the nine month anniversary of the 2020 Date of Grant, and the final 20% vested on the year anniversary of the 2020 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| November 29, 2023 Filed Dec 5, 2023 01:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 1,750 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001493152-23-043635 · ownership.xml · derivative · entry 2 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2030-10-01 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. Read SEC document |
| November 15, 2023 Filed Dec 5, 2023 01:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 3,334 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001493152-23-043635 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2023-11-15 F1 · derivative.exercise_date: 100% of the option vested on November 15, 2023, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| June 09, 2022 Filed Jun 14, 2022 06:30 UTC | Globis Acquisition Corp. GLAQU · Entity 126213 | OtherCommon Stock Purchase Warrant · Derivative | 20,000 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001493152-22-016643 · ownership.xml · derivative · entry 2 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-12-10 F3 · price: As described in the Form 8-K, in connection with the closing of the Business Combination, the private placement warrants were exchanged for warrants to acquire Ordinary Shares at an exercise price of $11.50 per share. F2 · derivative.exercise_date: The warrants became exercisable upon the completion of the Business Combination. Read SEC document |
| June 09, 2022 Filed Jun 14, 2022 06:30 UTC | Globis Acquisition Corp. GLAQU · Entity 126213 | OtherCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-016643 · ownership.xml · nonDerivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On June 9, 2022, the issuer consummated its initial business combination (the "Business Combination") with Forafric Global PLC. ("New Forafric"), a Gibraltar public company limited by shares. As described in Globis Acquisition Corp.'s Current Report on Form 8-K (File No. 333-262126) filed on June 9, 2022 (the "Form 8-K"), in connection with the closing of the Business Combination, each share of Common Stock was exchanged for one ordinary share, nominal value $0.001 per share, of New Forafric (each, an "Ordinary Share"). Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:01 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 57,500 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001493152-21-032873 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2031-12-28 F1 · derivative.exercise_date: 25% of the option vested on December 29, 2021 (the "Date of Grant"), with an additional 25% to vest on the three-month anniversary of the Date of Grant, a further 25% to vest on the six-month anniversary of the Date of Grant, and the final 25% to vest on the nine-month anniversary of the Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| December 29, 2021 Filed Jan 3, 2022 11:03 UTC | Globis Acquisition Corp. GLAQU · Entity 126213 | GiftCommon Stock Purchase Warrant · Derivative | 20,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001493152-22-000055 · ownership.xml · derivative · entry 2 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-12-10 F1 · derivative.exercise_date: The warrants will become exercisable on the completion of an initial business combination. Read SEC document |
| February 24, 2021 Filed Jan 3, 2022 11:03 UTC | Globis Acquisition Corp. GLAQU · Entity 126213 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-000055 · ownership.xml · nonDerivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 02:30 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 85,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-20-024403 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-12-22 F1 · derivative.exercise_date: 20% of the option vested on December 22, 2020 (the "Date of Grant"), with an additional 20% to vest on the three month anniversary of the Date of Grant, a further 20% to vest on the six month anniversary of the Date of Grant, a further 20% to vest on the nine month anniversary of the Date of Grant, and the final 20% to vest on the year anniversary of the Date of Grant. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:52 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 27,500 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001493152-20-020491 · ownership.xml · derivative · entry 5 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires 2029-12-04 F1 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:52 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 27,500 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001493152-20-020491 · ownership.xml · derivative · entry 4 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires 2028-08-14 F1 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:52 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 21,250 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001493152-20-020491 · ownership.xml · derivative · entry 3 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,250 shares Expires 2028-08-14 F1 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:52 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001493152-20-020491 · ownership.xml · derivative · entry 2 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-07-18 F1 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:52 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001493152-20-020491 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-04-27 F1 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 23:46 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 35,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001493152-20-018957 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-10-01 F1 · derivative.exercise_date: The option vested on October 1, 2020. Read SEC document |
| July 13, 2020 Filed Aug 28, 2020 19:02 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 27,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-20-016907 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2030-07-13 F1 · derivative.exercise_date: The option vested on July 13, 2020. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 20:50 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 27,500 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001213900-19-025511 · ownership.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2029-12-04 F1 · derivative.exercise_date: The option vested on December 4, 2019. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:33 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 27,500 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001615774-18-008226 · s112126_form4.xml · derivative · entry 2 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2028-08-14 F1 · derivative.exercise_date: Vesting is subject to the reporting person's continued service to the Issuer. F1 · balance_after: Vesting is subject to the reporting person's continued service to the Issuer. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:33 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 21,250 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001615774-18-008226 · s112126_form4.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 21,250 shares Expires 2028-08-14 Read SEC document |
| May 12, 2017 Filed May 16, 2017 17:07 UTC | NeuBase Therapeutics, Inc. OHRP · Entity 109568 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001387131-17-002848 · ferguson-form4_051217.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2022-05-11 F1 · derivative.exercise_date: 1/3 of the shares of common stock subject to the stock option became exercisable immediately, and 1/3 of the shares of common stock subject to the stock option will become exercisable on each of May 12, 2018 and May 12, 2019. Read SEC document |
| May 12, 2017 Filed Oct 18, 2017 18:00 UTC Amendment | NeuBase Therapeutics, Inc. OHRP · Entity 109568 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001387131-17-005086 · ferguson-form4a_051217.xml · derivative · entry 1 Ferguson Michael · CIK 0001607534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2022-05-11 F1 · shares: Reflects a reduction of options to purchase 250,000 shares of common stock subject to the stock option, the excess portion of shares of common stock subject to the stock options granted to the reporting person on May 12, 2017, in connection with the reporting person's appointment to the board of directors of the Issuer, which excess portion has been determined to have been in excess of annual plan limits set forth in the Issuer's 2016 Consolidated Stock Incentive Plan, and thus rescinded and canceled. F2 · derivative.exercise_date: 250,000 shares of common stock subject to the stock option became exercisable immediately, and 125,000 shares of common stock subject to the stock option will become exercisable on each of May 12, 2018 and May 12, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.